RxDoctor Payments Data

Sandeep Chandra, MD

Internal Medicine · Burbank, ILNPI 1063453876

Payments from drug & device makers

$3,198in general payments, 2019–2025

Across 143 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Pfizer$474
  • GSK$276
  • Novo Nordisk$242
  • Baxter Healthcare$199
  • Johnson & Johnson$151
  • plus $454 from 10 others

What the payments were for

  • Food & beverage$3,00594%
  • Education$120%
  • Other$1816%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,198 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$993,145
Medicare patients
623
Services billed
7,664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,406$437,014
JardianceEmpagliflozin300$190,089
TrulicityDulaglutide93$98,722
FarxigaDapagliflozin Propanediol154$94,584
Trelegy ElliptaFluticasone/Umeclidin/Vilanter95$87,441
JanuviaSitagliptin Phosphate128$76,776
OzempicSemaglutide48$56,293
XareltoRivaroxaban174$56,283
EntrestoSacubitril/Valsartan91$53,657
TradjentaLinagliptin62$34,676
ActemraTocilizumab26$33,008
Breo ElliptaFluticasone/Vilanterol41$23,603
Atorvastatin Calcium2,494$23,050
LinzessLinaclotide35$21,512
Spiriva HandihalerTiotropium Bromide34$20,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$474$437,0141,406 claims
AstraZenecaFarxiga, Lokelma, Breztri Aerosphere, Symbicort$1,401$139,149246 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$276$124,136165 claims
MerckJanuvia$16$76,776128 claims
Johnson & JohnsonXarelto, Procrit$151$72,965201 claims
Novo NordiskOzempic$242$56,29348 claims
AbbVieLinzess$21$21,51235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Burbank

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →